Upcoming Courses
27th Annual Summer Seminars: Psychopharmacology, 2016
Ross J. Baldessarini, MD, DSc (hon.)
This seminar will address the clinically important science of psychopharmacology as applied to treatment of schizophrenia, bipolar disorder, major depression, and anxiety disorders, with a focus on topics of importance for practicing clinicians. It will emphasize and critically address the evidence base that guides clinical practice in the use of psychotropic medicines to treat major psychiatric disorders, considering short-term and long-term efficacy and dosing of antipsychotic, mood-stabilizing, antidepressant drugs, and anti-anxiety agents as well as their adverse-effect risks. The seminar will also consider ways of enhancing clinically successful and safe prescribing, and consider critically the importance of applying psychopharmacologic treatments in the context of comprehensive clinical care of psychiatric patients.
- Describe the evidence supporting short-term and long-term treatment of patients with psychotic, bipolar, major depressive, and anxiety disorders;
- Evaluate treatment practices involving psychotropic drugs and develop strategies to improve clinical practice;
- Assess potentially severe adverse effects of psychotropic drug treatment, and improve skills in limiting risk and avoiding adverse events;
- Analyze the current relationship between treatment with psychotropic drugs and risk of mortality due to suicide and other causes of increased mortal risks in psychiatric patients;
- Better integrate psychopharmacology into comprehensive care of psychiatric patients;
- Critically assess advantages and limitations of psychopharmacology and its impact on the theory and practice of contemporary clinical psychiatry.
Additional Information
|
Friday, July 15, 2016 |
|
|
4:00-4:30 PM |
Registration |
|
4:30-6:30 PM |
Overview & Update on Psychopharmacology. Q&A |
|
Saturday, July 16, 2016 |
|
|
8:15-10:00 AM |
Evidence for the efficacy and effectiveness of treatments for acute mania, and recurrences of mania, bipolar depression, and mixed manic-depressive states. Q&A |
|
10:00-10:15 AM |
Continental Coffee Break |
|
10:15 AM-12:30 PM |
Overview of lithium and FDA-approved anticonvulsants and antipsychotic drugs. |
|
Sunday, July 17, 2016 |
|
|
8:15-10:00 AM |
Long term use of antidepressants to treat depression and anxiety. |
|
10:00-10:15 AM |
Continental Coffee Break |
|
10:15 AM-12:30 PM |
Options for management of treatment-resistant depression; practical aspects of psychotropic drug treatment and its effects on suicidal risk. |
|
12:30 PM |
Adjourn |
Beth Israel Deaconess Department of Psychiatry Foundation, Inc./Contact Hours: 10
Accreditation:
Physicians This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of pmiCME and The Continuing Education Program at Beth Israel Deaconess Medical Center. pmiCME is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION:
Weekend Seminar: pmiCME designates the live activity for a maximum of 10 AMA PRA Category 1 Credits™
The Royal College of Physicians and Surgeons of Canada recognizes conferences and workshops held outside of Canada that are developed by a university, academy, hospital, specialty society or college as accredited group learning activities.
AMA PRA Category 1 Credits™ claimed by physicians attending live events certified and organized in the United States for AMA PRA Category 1 Credits™ can be claimed through the agreement on mutual recognition of credits between UEMS and AMA, considered as being equal to the European Continuous Medical Education Credits(ECMEC©) granted by the UEMS. One AMA PRA Category 1 Credit™ is equivalent to one (1) hour of European EACCME Credit (ECMEC©), therefore up to 15 ECMEC© Credits are available. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.
Psychologists The Continuing Education Program at Beth Israel Deaconess Medical Center, a major teaching hospital of Harvard Medical School is approved by the American Psychological Association to offer continuing education for psychologists. The Continuing Education Program at Beth Israel Deaconess Medical Center, a major teaching hospital of Harvard Medical School maintains responsibility for this program and its content.
Counselors The Continuing Education Program at Beth Israel Deaconess Medical Center, a major teaching hospital of Harvard Medical School has been approved by NBCC as an Approved Continuing Education Provider, ACEP No. 5689. Programs that do not qualify for NBCC credit are clearly identified. The Continuing Education Program at Beth Israel Deaconess Medical Center, a major teaching hospital of Harvard Medical School is solely responsible for all aspects of the programs.
Social Workers For information on the status of the application to the Massachusetts Chapter of the National Association of Social Workers, please call 617-754-1265 or email: sjruiz@bidmc.harvard.edu.
Nurses Applications have been made for the following programs to the Massachusetts Association of Registered Nurses Inc. an approved provider of nursing credits by the American Nurses Credentialing Center’s Commission on Accreditation
Ross J. Baldessarini, MD, DSc (hon.) is a Professor of Psychiatry and in Neuroscience at Harvard Medical School and Director of the Psychopharmacology Program and International Consortium for Bipolar Disorder Research at McLean Hospital. Dr. Baldessarini is the recipient of many regional, national, and international research, mentoring, and teaching awards, and is on the Institute of Scientific Information list of most-cited authors in pharmacology and psychiatry. He has authored over 2100 scientific articles and several books, including Chemotherapy in Psychiatry, third edition. He also wrote the chapters on psychopharmacology for the standard American textbook of pharmacology, Goodman and Gilman’s Pharmacologic Basis of Therapeutics for several decades, and serves on editorial boards of leading journals in pharmacology and psychiatry.